MicroRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma

FEBS Letters

Volumn 585, Issue 12, 2011, Pages 1828-1834

  Zhou, Changchun ^a,b   Liu, Jibing ^b   Li, Yang ^c   Liu, Li ^a   Zhang, Xiaojiao ^a   Ma, Cheng Yuan ^c   Hua, Shu Cheng ^c   Yang, Ming ^a   Yuan, Qipeng ^a  

^a BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

ADAM9; Hepatocellular cancer; microRNA 1274a; Sorafenib

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE 9; ADAM PROTEIN; MICRORNA; MICRORNA 1274A; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RNA ANALYSIS; UPREGULATION;

ADAM PROTEINS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICRORNAS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 79958151325     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2011.04.040     Document Type: Article

References (32)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J. Clin. 55 2005 74 108 (Pubitemid 40372904)
2. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576 (Pubitemid 46890874)
3. Z.Y. Tang Hepatocellular carcinoma - cause, treatment and metastasis World J. Gastroenterol. 7 2001 445 454
4. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Häussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, J. Bruix, and SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 359 2008 378 390
5. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, J.S. Kim, R. Luo, J. Feng, S. Ye, T.S. Yang, J. Xu, Y. Sun, H. Liang, J. Liu, J. Wang, W.Y. Tak, H. Pan, K. Burock, J. Zou, D. Voliotis, and Z. Guan Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol. 10 2009 25 34
6. M. Colombo Sorafenib in advanced hepatocellular carcinoma: a further step toward personalized therapy of liver cancer Gastroenterology 136 2009 1832 1835
7. J. Bruix, M. Sherman, and Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236 (Pubitemid 43112690)
8. L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, D. Wilkie, S. Wilhelm, M. Lynch, and C. Carter Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res. 66 2006 11851 11858 (Pubitemid 46094197)
9. Y.H. Hwang, J.Y. Choi, S. Kim, E.S. Chung, T. Kim, S.S. Koh, B. Lee, S.H. Bae, J. Kim, and Y.M. Park Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma Hepatol. Res. 29 2004 113 121 (Pubitemid 38667508)
10. M.A. Avila, C. Berasain, B. Sangro, and J. Prieto New therapies for hepatocellular carcinoma Oncogene 25 2006 3866 3884 (Pubitemid 43980482)
11. A. de La Coste, B. Romagnolo, P. Billuart, C.A. Renard, M.A. Buendia, O. Soubrane, M. Fabre, J. Chelly, C. Beldjord, A. Kahn, and C. Perret Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas Proc. Natl. Acad. Sci. USA 95 1998 8847 8851 (Pubitemid 28350577)
12. F. Carlomagno, S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S.M. Wilhelm, and M. Santoro BAY 43-9006 inhibition of oncogenic RET mutants J. Natl. Cancer Inst. 98 2006 326 334 (Pubitemid 43338212)
13. S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, R.A. Smith, B. Schwartz, R. Simantov, and S. Kelley Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat. Rev. Drug Disc. 5 2006 835 844 (Pubitemid 44480537)
14. K. Kohga, T. Takehara, T. Tatsumi, H. Ishida, T. Miyagi, A. Hosui, and N. Hayashi Sorafenib inhibits the shedding of major histocompatibility complex class I - related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9 Hepatology 51 2010 1264 1273
15. V. Ambros The functions of animal microRNAs Nature 431 2004 350 355 (Pubitemid 39265675)
16. S. Li, H. Fu, Y. Wang, Y. Tie, R. Xing, J. Zhu, Z. Sun, L. Wei, and X. Zheng MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma Hepatology 49 2009 1194 1202
17. J. Ji, J. Shi, A. Budhu, Z. Yu, M. Forgues, S. Roessler, S. Ambs, Y. Chen, P.S. Meltzer, C.M. Croce, L.X. Qin, K. Man, C.M. Lo, J. Lee, I.O. Ng, J. Fan, Z.Y. Tang, H.C. Sun, and X.W. Wang MicroRNA expression, survival, and response to interferon in liver cancer N. Engl. J. Med. 361 2009 1437 1447
18. P. Pineau, S. Volinia, K. McJunkin, A. Marchio, C. Battiston, B. Terris, V. Mazzaferro, S.W. Lowe, C.M. Croce, and A. Dejean miR-221 overexpression contributes to liver tumorigenesis Proc. Natl. Acad. Sci. USA 107 2010 264 269
19. C. Braconi, N. Valeri, P. Gasparini, N. Huang, C. Taccioli, G. Nuovo, T. Suzuki, C.M. Croce, and T. Patel Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes Clin. Cancer Res. 16 2010 957 966
20. S. Shimizu, T. Takehara, H. Hikita, T. Kodama, T. Miyagi, A. Hosui, T. Tatsumi, H. Ishida, T. Noda, H. Nagano, Y. Doki, M. Mori, and N. Hayashi The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma J. Hepatol. 52 2010 698 704
21. S. Bai, M.W. Nasser, B. Wang, S.H. Hsu, J. Datta, H. Kutay, A. Yadav, G. Nuovo, P. Kumar, and K. Ghoshal MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib J. Biol. Chem. 284 2009 32015 32027
22. G.A. Calin, and C.M. Croce MicroRNA signatures in human cancers Nat. Rev. Cancer 6 2006 857 866 (Pubitemid 44629897)
23. A. Esquela-Kerscher, and F.J. Slack Oncomirs - microRNAs with a role in cancer Nat. Rev. Cancer 6 2006 259 269
24. T.E. Miller, K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C.L. Shapiro, S. Jacob, and S. Majumder MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 J. Biol. Chem. 283 2008 29897 29903
25. M.W. Nasser, J. Datta, G. Nuovo, H. Kutay, T. Motiwala, S. Majumder, B. Wang, S. Suster, S.T. Jacob, and K. Ghoshal Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1 J. Biol. Chem. 283 2008 33394 33405
26. V. Groh, J. Wu, C. Yee, and T. Spies Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation Nature 419 2002 734 738 (Pubitemid 35177960)
27. K. Tao, N. Qian, Y. Tang, Z. Ti, W. Song, D. Cao, and K. Dou Increased expression of a disintegrin and metalloprotease-9 in hepatocellular carcinoma: implications for tumor progression and prognosis Jpn. J. Clin. Oncol. 40 2010 645 651
28. J.L. Fry, and A. Toker Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration Cancer Res. 70 2010 8187 8198
29. Y. Izumi, M. Hirata, H. Hasuwa, R. Iwamoto, T. Umata, K. Miyado, Y. Tamai, T. Kurisaki, A. Sehara-Fujisawa, S. Ohno, and E. Mekada A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor EMBO J. 17 1998 7260 7272 (Pubitemid 29002695)
30. E. Dyczynska, D. Sun, H. Yi, A. Sehara-Fujisawa, C.P. Blobel, and A. Zolkiewska Proteolytic processing of delta-like 1 by ADAM proteases J. Biol. Chem. 282 2007 436 444 (Pubitemid 47076599)
31. E. Parkin, and B. Harris A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10 J. Neurochem. 108 2009 1464 1479
32. T. Tousseyn, A. Thathiah, E. Jorissen, T. Raemaekers, U. Konietzko, K. Reiss, E. Maes, A. Snellinx, L. Serneels, O. Nyabi, W. Annaert, P. Saftig, D. Hartmann, and B. De Strooper ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase J. Biol. Chem. 284 2009 11738 11747